References

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pharmacoeconomic Report: Esketamine Hydrochloride (Spravato): (Janssen Inc.): Indication: Major Depressive Disorder in Adults [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr.

Cover of Pharmacoeconomic Report: Esketamine Hydrochloride (Spravato)

Pharmacoeconomic Report: Esketamine Hydrochloride (Spravato): (Janssen Inc.): Indication: Major Depressive Disorder in Adults [Internet].

Show details

Contents

< PrevNext >

References

1.: Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. The American journal of psychiatry. 2019;176(6):428–438. [PubMed: 31109201]
2.: Spravato (esketamine hydrochloride): 28 mg, solution for intranasal use [draft product monograph]. Toronto: Janssen Inc.; 2019.
3.: Pharmacoeconomic evaluation. In: CDR submission: Spravato (esketamine hydrochloride), 28 mg, solution for intranasal use [CONFIDENTIAL manufacturer’s submission]. Toronto: Janssen Inc.; 2019 July.
4.: Bergfeld IO, Mantione M, Figee M, Schuurman PR, Lok A, Denys D. Treatment-resistant depression and suicidality. Journal of affective disorders. 2018;235:362–367. [PubMed: 29665520]
5.: Statistics Canada. Deaths and mortality rates, by age group. Statistics Canada; 2017: https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1310071001. Accessed 2020 Feb 21.
6.: Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. The American journal of psychiatry. 2006;163(11):1905–1917. [PubMed: 17074942]
7.: Edwards SJ, Hamilton V, Nherera L, Trevor N. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health technology assessment (Winchester, England). 2013;17(54):1–190. [PMC free article: PMC4781298] [PubMed: 24284258]
8.: Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Canadian journal of psychiatry Revue canadienne de psychiatrie. 2016;61(9):540–560. [PMC free article: PMC4994790] [PubMed: 27486148]
9.: National Institute for Health and Care Excellence. Depression in adults: recognition and management. London (UK): NICE; 2009: https://www.nice.org.uk/guidance/cg90. Accessed 2020 Feb 21. [PubMed: 31990491]
10.: Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. The British journal of psychiatry : the journal of mental science. 2007;190:287–292. [PubMed: 17401033]
11.: Ontario Ministry of Health Long-Term C. Ontario drug benefit formulary/comparative drug index. 2019; https://www.formulary.health.gov.on.ca/formulary/. Accessed 2020 Feb 18.
12.: Living in Canada. Registered Nurse Salary Canada. 2020: https://www.livingin-canada.com/salaries-for-registered-nurses.html. Accessed 2020 Feb 21.
13.: IQVIA. Burden of Treatment-Resistant Depression in Ontario. 2018. Accessed 2020 Feb 21.
14.: Ontario Ministry of Health Long-Term C. Schedule of benefits for physician services under the Health Insurance Act: effective March 1, 2016. Toronto (ON): The Ministry of Health and Long-Term Care; 2015: http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master20181115.pdf. Accessed 2020 Mar 24.
15.: Institute for Clinical and Economic Review. Esketamine for the Treatment of Treatment-Resistant Depression: Effectiveness and Value. Boston (USA): ICER; 2019: https://icer-review.org/wp-content/uploads/2018/10/ICER_TRD_Final_Evidence_Report_062019.pdf. Accessed 2020 Mar 6.
16.: CADTH Rapid Response Report: Intravenous Ketamine for Adults with Treatment-Resistant Depression or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, CostEffectiveness and Guidelines. Ottawa (ON): CADTH; 2019: https://www.cadth.ca/sites/default/files/pdf/htis/2019/RC1203%20IV%20Ketamine%20for%20Depression%20and%20PTSD%20Final.pdf. Accessed 2020 Mar 03.
17.: Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. The American journal of psychiatry. 2013;170(10):1134–1142. [PMC free article: PMC3992936] [PubMed: 23982301]
18.: Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. The American journal of psychiatry. 2016;173(8):816–826. [PubMed: 27056608]
19.: Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. The Journal of clinical psychiatry. 2015;76(3):247–252. [PubMed: 25271445]
20.: Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Current Medical Research and Opinion. 2017;33(4):701–711. [PubMed: 28035869]
21.: Zhou X, Keitner GI, Qin B, et al. Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis. The international journal of neuropsychopharmacology. 2015;18(11):pyv060. [PMC free article: PMC4756722] [PubMed: 26012350]
22.: National Institute for Health and Care Excellence. Appraisal consultation document: Esketamine for treating treatment-resistant depression. London (UK): NICE; 2020: https://www.nice.org.uk/guidance/gid-ta10371/documents/129. Accessed 2020 Mar 03.
23.: Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular psychiatry. 2018. [PMC free article: PMC6447473] [PubMed: 30283029]
24.: Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Medical decision making : an international journal of the Society for Medical Decision Making. 2006;26(4):410–420. [PMC free article: PMC2634296] [PubMed: 16855129]
25.: Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS drugs. 2004;18(13):911–932. [PubMed: 15521793]
26.: Parikh SV, Quilty LC, Ravitz P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments. Canadian journal of psychiatry Revue canadienne de psychiatrie. 2016;61(9):524–539. [PMC free article: PMC4994791] [PubMed: 27486150]
27.: Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. Canadian journal of psychiatry Revue canadienne de psychiatrie. 2016;61(9):561–575. [PMC free article: PMC4994792] [PubMed: 27486154]
28.: Government BC. BC PharmaCare formulary search. 2019; https://pharmacareformularysearch.gov.bc.ca. Accessed 2020 Feb 28.
29.: Alberta H. Interactive drug benefit list. 2019; https://idbl.ab.bluecross.ca/idbl/load.do. Accessed 2020 Feb 18.
30.: Fluvoxamine (fluvoxamine maleate): 50 mg and 100 mg tablets [product monograph]. Teva Canada Limited; 2019: https://pdf.hres.ca/dpd_pm/00054136.PDF. Accessed 2020 Feb 18.
31.: Government of Saskatchewan. Drug Plan and Extended Benefits Branch. 2020: http://formulary.drugplan.ehealthsask.ca/SearchFormulary. Accessed 2020 Feb 18.
32.: DeltaPA. [Ottawa (ON)]: IQVIA; 2019: https://www.iqvia.com/. Accessed 2020 Feb 18.
33.: Ravindran AV, Kennedy SH, O’Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. The Journal of clinical psychiatry. 2008;69(1):87–94. [PubMed: 18312042]
34.: Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa (ON): CADTH; 2017: https://www.cadth.ca/dv/guidelines-economic-evaluation-health-technologies-canada-4th-edition. Accessed 2020 Feb 20.
35.: Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. Journal of affective disorders. 1998;48(1):25–36. [PubMed: 9495599]

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK572202

Contents

< PrevNext >

PubReader
Print View
Cite this Page
Pharmacoeconomic Report: Esketamine Hydrochloride (Spravato): (Janssen Inc.): Indication: Major Depressive Disorder in Adults [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. References.
PDF version of this title (936K)